SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PEG4-aminooxy-MMAF

Cat. No.: HY-128968

CAS No.: 1415246-35-3

Molecular Formula: $C_{47}H_{82}N_6O_{12}$

Molecular Weight: 923.19

Target: Drug-Linker Conjugates for ADC; Microtubule/Tubulin

Pathway: Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Storage: -20°C, protect from light

* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro

H_2O : ≥ 100 mg/mL (108.32 mM)

DMSO : 100 mg/mL (108.32 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.0832 mL	5.4160 mL	10.8320 mL
	5 mM	0.2166 mL	1.0832 mL	2.1664 mL
	10 mM	0.1083 mL	0.5416 mL	1.0832 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4[1].

IC_{50} & Target

Auristatin

In Vitro

Antibody-drug conjugates (ADCs) carry a highly potent small-molecule toxin covalently connected on the antibody via a proper linker. For therapeutic ADCs in cancer treatment, the antibody targets specific antigen of tumor cell surface with high

binding affinity, thereafter the intact ADC was internalized into the tumor cells with the antigen and digested in the lysosome to release the antitumor toxin[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Mukherjee A, et al. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers (Basel). 2024 Oct 17;16(20):3517.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA